Denied on prior authorisation twice, approved on the third attempt after a peer-to-peer, and the only thing that changed was who was doing the talking.
The bit I cannot resolve on my own is what actually works on a prior-authorisation denial, as opposed to the list of things that sound like they should work.
Practical detail welcome, however dull — the duller the better.
EndoResFellow said:Denied on prior authorisation twice, approved on the third attempt after a peer-to-peer, and the only thing that changed was who was doing the…
Telehealth prescriber review for cost and coverage: I've used 4 different telehealth platforms to get my GLP-1 prescription. Comparison:
| Feature | Platform A | Platform B | Platform C |
|---|---|---|---|
| Initial Consult | $68 | $98 | $0 |
| Monthly Follow-up | $48 | Included | $53 |
| Prescription Speed | Same day | 24-48 hours | Same day |
| Lab Monitoring | Required | Optional | Required |
I settled on the one that required labs — it shows they care about safety, not just prescribing volume.
BenResearch_OR said:Telehealth prescriber review for cost and coverage: I've used 4 different telehealth platforms to get my GLP-1 prescription.
BenResearch_OR said:...regarding the discontinuation data for cost and coverage...
I want to reframe the discontinuation narrative. We don't say "insulin fails because blood sugar rises when you stop it." We don't say "antihypertensives fail because BP goes up without them."
Why do we apply different logic to anti-obesity medications? The answer is stigma. We still, unconsciously, believe obesity is about willpower rather than biology. The discontinuation data actually PROVES it's a chronic biological condition requiring ongoing treatment.
This reframing isn't semantic — it has implications for insurance coverage, treatment duration, and patient expectations.
Janoshik Analytical — Independent Testing
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesGL Biochem (Shanghai) Ltd. — Direct Manufacturer
Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemEndoResFellow said:Denied on prior authorisation twice, approved on the third attempt after a peer-to-peer, and the only thing that changed was who was doing the…
Second this. The detail I would add is minor and it is already implied above.
Clinical perspective, offered as context rather than as advice.
EndoResFellow said:...my insurance denied cost and coverage coverage because...
Insurance denial is the single biggest barrier to GLP-1 access. Let me share the appeal framework that worked for me and several community members:
- Document medical necessity (BMI, comorbidities, failed alternatives)
- Reference clinical practice guidelines (AGA, AACE, Endocrine Society)
- Cite cost-effectiveness data (preventing diabetes/surgery saves money long-term)
- Request peer-to-peer review between your doctor and the plan's medical director
- File external appeal with your state insurance department if internal appeal fails
Don't accept the first denial. The appeal process exists for a reason.